Lilly USA Updates Health Education Program to Help Patients with Depression Build Network of Support

Eli Lilly and CompanyThe Support Partners Program offered by Lilly USA shows individuals with depression ways to build their own support group, which, in turn, can help them better deal with their depression symptoms. The Support Partners Program can also help people better understand the illness and the importance of seeking help from a health care professional.

Available at SupportPartnersProgram.com, all materials are available in both English and Spanish and address a variety of topics related to depression, including a step-by-step guide that may help with the possibility of getting better.

"Lilly is proud to introduce its updated Support Partners Program as part of our extensive health education offerings," said Alex M. Azar II, vice president, Lilly USA. "We believe it is vital that we work together with patients and others in the health care system to improve patient care and overall public health. Providing these resources for patients is just one of our many initiatives."

Program components in the Support Partners Kit include: Managing Your Depression, which provides helpful tips, tools and steps to follow on building a support group and managing symptoms; Being a Support Partner, which includes information for the selected partner on everyday steps to help their friend or loved one with depression; Shared Guidebook, which features information designed for the patient and his or her Support Partner to focus on setting goals, tracking progress and noting important information; Ages and Stages, which outlines how women's experiences with depression can change during their lives; Canine Companions, which offers information about how dogs can have a positive effect on the overall health and emotional well-being of patients with depression.

In addition to Support Partners, Lilly offers a number of other educational materials online at lillyforbetterhealth.com. A few of these include:

  • A Healthy You! - America's Guide to Healthy Living is a 148-page book that brings together a wide variety of health information from reliable sources in a simple, easy-to-use format. What makes the book unique is an extensive list of resources available to the public in each state. These state-specific resources help connect people to health programs and agencies in their area, making the search for health information easier. The book is available in English and Spanish.
  • F.A.C.E. Diabetes Campaign is a grassroots movement focused on targeting African-Americans to help individuals and families overcome key barriers to success in living with diabetes.
  • Healthy Family Home is a national program designed to help families make moderate changes in how they eat, play and spend time together. The program encourages families to choose healthy goals that make sense for them and that lead to sustained improvements. Materials are in English and Spanish.
  • Lilly's patient assistance programs provide access to medications for patients in need. Over the past three years, Lilly has assisted more than 510,000 patients in the United States and distributed medications, valued at over $765 million.

About Eli Lilly and Company
Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. For additional information on Health Education Answers or Lilly's other patient care and disease management programs, visit www.lillyforbetterhealth.com.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara┬« (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...